News & Updates
Filter by Specialty:
Venetoclax-obinutuzumab ± ibrutinib induces PFS benefit in CLL
A time-limited regimen of venetoclax plus obinutuzumab with or without ibrutinib improved progression-free survival (PFS) in fit, treatment-naïve patients with chronic lymphocytic leukaemia (CLL), according to results of the phase III GAIA/CLL13 trial presented at EHA 2022.
Venetoclax-obinutuzumab ± ibrutinib induces PFS benefit in CLL
13 Jul 2022
Can very low-risk breast cancer patients be spared from postop radiotherapy?
Adjuvant radiotherapy (RT) may be omitted in women with very low-risk breast cancer who have had breast conserving surgery (BCS) and have been receiving endocrine therapy, according to findings from the LUMINA study.
Can very low-risk breast cancer patients be spared from postop radiotherapy?
12 Jul 2022
Sabizabulin for metastatic castration-resistant prostate cancer clears phase early trial
The oral cytoskeleton disruptor sabizabulin shows antitumour activity in men with metastatic castration-resistant prostate cancer, while having a favourable safety profile, as shown in the results of a phase Ib/II trial.
Sabizabulin for metastatic castration-resistant prostate cancer clears phase early trial
10 Jul 2022
Triplet regimen works against triple-negative breast cancer
Treatment with a novel combination of famitinib, camrelizumab, and nab-paclitaxel appears safe and effective in patients with advanced immunomodulatory triple-negative breast cancer (TNBC), as shown in the results of the phase II FUTURE-C-Plus trial.
Triplet regimen works against triple-negative breast cancer
08 Jul 2022
Age the biggest risk factor for COVID-19 mortality in haematological cancer patients
A study conducted in England has shown that in patients with haematological malignancy, the risk of COVID-19–related mortality is greatly influenced by age.